Symbiosis Pharmaceutical Services, a sterile fill finish contract manufacturing organization (CMO), has manufactured its first 10,000 vial batch at the company’s new facility in Stirling, UK. 

The project supports the development of a cancer immunotherapy currently in Phase III trials. The production batch of 10,000 vials marks a milestone in the company’s planned expansion of its sterile manufacturing capacity.

The FDA-inspected and MHRA-licensed facility supports clients from clinical trials through to commercial supply. By increasing capacity and enhancing operational flexibility, the expansion enables the company to deliver larger batch sizes, accommodate additional programs, and provide support for clients preparing for late-stage and commercial launch.

“Manufacturing this first batch of 10,000 vials in our state-of-the-art facility is a pivotal moment for Symbiosis,” said Colin MacKay, CEO of Symbiosis. “It demonstrates the continued evolution of our business, from a start-up to a trusted global partner, and reflects our unwavering commitment to ensuring patients receive the life-changing treatments they depend on.”

“With our expanded capabilities, we are better equipped than ever to support our clients as they advance critical therapies. We are proud to play an integral part in helping innovative treatments move from development to commercial reality.”